Literature DB >> 29472163

Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia.

Olesya Ajnakina1, Henriette Thisted Horsdal2, John Lally3, James H MacCabe4, Robin M Murray4, Christiane Gasse2, Theresa Wimberley2.   

Abstract

Large-scale pharmacoepidemiological research on treatment resistance relies on accurate identification of people with treatment-resistant schizophrenia (TRS) based on data that are retrievable from administrative registers. This is usually approached by operationalising clinical treatment guidelines by using prescription and hospital admission information. We examined the accuracy of an algorithm-based definition of TRS based on clozapine prescription and/or meeting algorithm-based eligibility criteria for clozapine against a gold standard definition using case notes. We additionally validated a definition entirely based on clozapine prescription. 139 schizophrenia patients aged 18-65years were followed for a mean of 5years after first presentation to psychiatric services in South-London, UK. The diagnostic accuracy of the algorithm-based measure against the gold standard was measured with sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). A total of 45 (32.4%) schizophrenia patients met the criteria for the gold standard definition of TRS; applying the algorithm-based definition to the same cohort led to 44 (31.7%) patients fulfilling criteria for TRS with sensitivity, specificity, PPV and NPV of 62.2%, 83.0%, 63.6% and 82.1%, respectively. The definition based on lifetime clozapine prescription had sensitivity, specificity, PPV and NPV of 40.0%, 94.7%, 78.3% and 76.7%, respectively. Although a perfect definition of TRS cannot be derived from available prescription and hospital registers, these results indicate that researchers can confidently use registries to identify individuals with TRS for research and clinical practices.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clozapine; Negative predictive value; Positive predictive value; Schizophrenia; Sensitivity; Specificity; Treatment resistance; Validation

Mesh:

Substances:

Year:  2018        PMID: 29472163     DOI: 10.1016/j.schres.2018.02.017

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

1.  DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia.

Authors:  Eilis Hannon; Emma L Dempster; Georgina Mansell; Joe Burrage; Nick Bass; Marc M Bohlken; Aiden Corvin; Charles J Curtis; David Dempster; Marta Di Forti; Timothy G Dinan; Gary Donohoe; Fiona Gaughran; Michael Gill; Amy Gillespie; Cerisse Gunasinghe; Hilleke E Hulshoff; Christina M Hultman; Viktoria Johansson; René S Kahn; Jaakko Kaprio; Gunter Kenis; Kaarina Kowalec; James MacCabe; Colm McDonald; Andrew McQuillin; Derek W Morris; Kieran C Murphy; Colette J Mustard; Igor Nenadic; Michael C O'Donovan; Diego Quattrone; Alexander L Richards; Bart Pf Rutten; David St Clair; Sebastian Therman; Timothea Toulopoulou; Jim Van Os; John L Waddington; Patrick Sullivan; Evangelos Vassos; Gerome Breen; David Andrew Collier; Robin M Murray; Leonard S Schalkwyk; Jonathan Mill
Journal:  Elife       Date:  2021-02-26       Impact factor: 8.140

2.  Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis.

Authors:  Daniela Polese; Michele Fornaro; Mario Palermo; Vincenzo De Luca; Andrea de Bartolomeis
Journal:  Front Psychiatry       Date:  2019-04-17       Impact factor: 4.157

Review 3.  DNA methylation and regulation of gene expression: Guardian of our health.

Authors:  Gaurab Aditya Dhar; Shagnik Saha; Parama Mitra; Ronita Nag Chaudhuri
Journal:  Nucleus (Calcutta)       Date:  2021-08-16

4.  A predictor model of treatment resistance in schizophrenia using data from electronic health records.

Authors:  Giouliana Kadra-Scalzo; Daniela Fonseca de Freitas; Deborah Agbedjro; Emma Francis; Isobel Ridler; Megan Pritchard; Hitesh Shetty; Aviv Segev; Cecilia Casetta; Sophie E Smart; Anna Morris; Johnny Downs; Søren Rahn Christensen; Nikolaj Bak; Bruce J Kinon; Daniel Stahl; Richard D Hayes; James H MacCabe
Journal:  PLoS One       Date:  2022-09-19       Impact factor: 3.752

5.  Efficacy of Asenapine in Schizophrenia Resistant to Clozapine Combined with Electroconvulsive Therapy: A Case Report.

Authors:  Shinichiro Ochi; Saori Inoue; Yuta Yoshino; Hideaki Shimizu; Jun-Ichi Iga; Shu-Ichi Ueno
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-11-20       Impact factor: 2.582

6.  Ursodeoxycholic acid augmentation in treatment-refractory schizophrenia: a case report.

Authors:  Mohsen Khosravi
Journal:  J Med Case Rep       Date:  2020-09-01

7.  Structural Covariance of Cortical Gyrification at Illness Onset in Treatment Resistance: A Longitudinal Study of First-Episode Psychoses.

Authors:  Olesya Ajnakina; Tushar Das; John Lally; Marta Di Forti; Carmine M Pariante; Tiago Reis Marques; Valeria Mondelli; Anthony S David; Robin M Murray; Lena Palaniyappan; Paola Dazzan
Journal:  Schizophr Bull       Date:  2021-10-21       Impact factor: 9.306

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.